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doi:10.1016/j.jmii.2011.12.005Background and Purpose: Cryptococcus species are the most common causative agents of
fungal meningitis. Different populations may show different clinical manifestations and
outcomes. In this retrospective study, we investigated these differences in patients with
and without HIV infection.
Methods: From 1995 to 2009, we collected data from HIV-infected or HIV-uninfected patients
aged 18 years or over who had cryptococcal meningitis (CM) in a medical center in Taiwan. We
reviewed and analyzed their demographic data, clinical manifestations, therapeutic strategies
and outcomes.
Results: Among the 72 patients with CM, 19 HIV-infected patients were predominantly younger
males, and all of them had AIDS status when CM was diagnosed. In contrast, the 53 HIV-
uninfected patients were mostly older males with underlying diseases. The time from initial
symptoms to diagnosis was shorter in HIV-infected patients (median 10 vs. 18 days,
p Z 0.048). The HIV-infected patients presented with less pleocytosis (p Z 0.003) and lower
protein levels in the cerebrospinal fluid (CSF), but a higher proportion had positive results for
cryptococci in the CSF (90% vs. 60%, p Z 0.02) and blood (53% vs. 21%, p Z 0.009) cultures.
Surgical drains and repeated lumbar punctures for the management of increased intracranial
pressure were performed in 47% of the HIV-infected patients and 38% of the HIV-uninfected
patients. A lower mortality rate was observed in the HIV-infected patients (p Z 0.038). OnInfectious Diseases, Department of Internal Medicine, China Medical University Hospital, Number 2
g City 40447, Taiwan.
.com (M.-W. Ho).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Cryptococcal meningitis in adult 297multivariate analysis, initial CD4 count 20/mm3 was an indicator of death or relapse in HIV-
infected patients. In the HIV-uninfected group, the initial high cryptococcal antigen titer in the
CSF (1:512) and hydrocephalus were related to unsatisfactory outcomes.
Conclusion: In addition to well-known differences, we found a lower mortality in HIV-infected
patients than in HIV-uninfected patients. Cryptococci and inflammation in the central nervous
system may play important roles in the pathogenesis of CM. Low intensity of inflammation and
effective surgical CSF drains for increased intracranial pressure and cryptococci removal may
contribute to lower mortality in HIV-infected patients.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cryptococci are environmental fungi that can cause infec-
tious diseases in humans. Cryptococcus neoformans and
Cryptococcus gattii are the most common pathogenic
species across the worldwide and can be classified into five
serotypes.1,2 Risk factors for cryptococcal infections,
including infection with HIV, liver cirrhosis, diabetes mel-
litus, solid organ transplantation, malignancies, rheuma-
tologic diseases, corticosteroid use and chronic kidney
disease, are well-documented.2,3 Occasionally, these
pathogens also infect immunocompetent patients.4
The central nervous system (CNS) is a common site for
cryptococcal infection. Cryptococcal meningitis (CM) is one
of the most common opportunistic infections in HIV-
infected patients.5,6 Similarly, the pathogen can also
infect HIV-uninfected patients causing severe meningitis.4
This type of infection causes high mortality rates in HIV-
infected (9%e55%) and HIV-uninfected patients (15%e
44%), even with appropriate treatment.4,6e8 Therefore, the
diagnosis and treatment of CM remains challenging for
clinicians.
Different clinical presentations of CM in HIV-infected
and HIV-uninfected patients have been described.4,5,7 Some
researchers have compared mortality the rates of HIV-
infected and HIV-uninfected patients,8e12 but the results
have been inconsistent and this prompted us to investigate
this controversial issue.Methods
Patients and definitions
From 1995 to 2009 we conducted a retrospective study at
China Medical University Hospital (CMUH, 2000 beds in mid-
Taiwan), a tertiary hospital. We enrolled all CM patients
aged 18 years or over. CM was defined as isolation of
Cryptococcus species from cerebrospinal fluid (CSF)
culture, positive CSF India ink or positive CSF cryptococcal
antigen (CrAg) titer, and consistent clinical features of
meningitis. The diagnosis and classification of HIV infec-
tion, AIDS status and opportunistic infection/malignancy
were performed on the basis of the standard criteria
proposed by the US Centers for Disease Control and
Prevention in 1993.13 Predisposing factors of CM were
identified in all of our patients.2,3 Corticosteroid useencompassed that those who could not withdraw from
corticosteroids or those who required at least prednisolone
20 mg daily. The Charlson comorbidity score was used to
evaluate comorbidity status. The time from the initial
symptoms to the time of definite diagnosis was considered
the symptom duration.11
Clinical symptoms and all laboratory data were recorded
on presentation to our hospital. For treatment classification,
the patients who received initial antifungal therapy for at
least 7 dayswere divided into different groups (amphotericin
B dosage: 0.5e1.0 mg/kg daily; fluconazole dosage:
400e800 mg daily; flucytosine dosage: 100 mg/kg daily; lipid
amphotericin B dosage 3e5 mg/kg daily). Flucytosine and
lipid amphotericin B had been available since 2007.14,15
Repeated lumbar punctures and temporary drains like
Ommaya reservoirs, lumbar drains or external ventricular
drains for increased intracranial pressure (IICP) control were
also analyzed. Permanent shunts for long-term CSF drainage
were collected separately.
All patients were followed up until death or for at least
6 months after discontinuation of antifungal therapy.
Outcomes4,16 were categorized as:
 cure/success: a drug-free interval >1 year, and no
reappearance of symptoms;
 improved: the same definition for cure/success but the
last follow-up examination or death occurred within
a year;
 fail: death due to first treated CM;
 relapse: defined as for improved, but with reappear-
ance of symptoms with CSF culture/India ink proof
after therapy had been stopped; and
 indeterminate: death due to causes other than CM, and
the treatment course was incomplete.
The outcomes were further classified as satisfactory
(cure/success or improved) and unsatisfactory (death,
relapse or indeterminate).4 Patients in the satisfactory
group were evaluated further for sequelae.
Laboratory methods
In cases of CM, an initial lumbar puncture was performed in
each patient and open pressure was recorded. CSF and
blood samples were collected for complete blood cell
counts and differential counts, glucose, protein, culture
and CrAg tests; a CSF staining with India ink was also
298 C.-H. Liao et al.performed. The titers of CrAg in serum and CSF were
measured using the CALAS Cryptococcal Antigen Latex
Agglutination System (Meridian Bioscience Inc. Cincinnati,
Ohio, USA). All laboratory data and microbiological exami-
nations were performed at the CMUH laboratory. All
images, including chest film and computed tomography
(CT) or magnetic resonance imaging (MRI) images of the
brain, were analyzed according to the reports of
radiologists.
Statistical analysis
Continuous data were presented as mean and standard
deviation or median and range. Continuous variables were
calculated using the Student t test, and categorical variables
were analyzed using the Chi-squared test or Fisher’s exact
test if any expected value was below five. Kaplan-Meier
analysis was used to obtain the survival curve. A p-value
<0.05 was considered statistically significant.
For outcome analysis, clinical presentations, laboratory
data and treatment methods were all analyzed as factors
using logistic regression in both groups. Variables with
p < 0.15 were entered into further multivariate analysis
with forward stepwise regression, leaving only variables
with p < 0.05. All analyses were two-sided and performed
using the Statistical Package for the Social Sciences version
17.0 software (SPSS, Inc., Chicago, IL, USA).
Results
Demographic data
During the study period, 72 patients with CM (19 HIV-
infected and 53 HIV-uninfected patients) were identified,
and the male sex was predominant in both groups (Table 1).Table 1 Demographics and characteristics
HIV-i
Male/Female, n/n 17/2
Age, mean no. years  SD# 33.3
Predisposing factors
Corticosteroid use, n (%) 0/19
Diabetes mellitus, n (%) 0/19
Liver cirrhosis, n (%) 0/19
Chronic kidney disease, n (%) 0/19
Autoimmune disease, n (%) 0/19
Solid organ transplant, n (%) 0/19
Malignancy, n (%) 2/19
Concurrent opportunistic infections, n (%) 14/1
CD4,/mm3, median (range) 28.5
HIV viral load, log10 copies/mL, mean  SD# 4.84
Charlson comorbidity index, mean  SD# 6.7 
CM, cryptococcal meningitis; NA, not applicable; SD, standard deviat
* p < 0.05; #student’s t test.
a Systemic lupus erythematosus (2/53), autoimmune hemolytic ane
b Kaposi’s sarcoma of the lungs (1/19) and duodenal lymphoma (1/
c Lymphoma (2/53), hematological malignancy (2/53), prostate can
d Opportunistic infection: Pneumocystis jiroveci pneumonia (5/19)
bacterium (2/19), herpes simplex (2/19), cytomegalovirus (1/19).Compared to the HIV-uninfected group, those with HIV
were younger (mean age: 33.3 years vs. 55.3 years,
p < 0.001). Individuals in the HIV-infected group all had CD4
counts <200/mm3. The majority of HIV-infected patients
had concurrent opportunistic infections (74%) and two
patients had AIDS-related malignancies. Among those with
HIV, 14 patients had been diagnosed with HIV infection
before the presentation of CM and 11 had received anti-
retroviral therapy (ART) at some point (five patients
without regular ART; and six patients with ART for <4
months). The median CD4 count among these 11 patients
was 37/mm3 (range: 10e140/mm) and their median viral
load was 5.3 log copies/mL (range: 2.6e5.7 log copies/mL).
Five patients were newly diagnosed with HIV infection on
the presentation of CM. In the HIV-uninfected group, 35
patients (66%) had at least one predisposing factor and 18
patients (34%) had more than one factor for CM. The
Charlson comorbidity score was significantly higher among
the HIV-infected patients than among the HIV-uninfected
patients (6.7 vs. 4.7, p Z 0.014).
Presentations and laboratory data
As shown in Table 2, headache and fever were the most
common clinical presentations in patients with CM. More
HIV-uninfected patients presented with visual symptoms
(p Z 0.031) and were more likely to present with altered
mental status, seizures and auditory symptoms than the
HIV-infected patients. Three HIV-infected patients without
neurological symptoms were diagnosed after lumbar punc-
ture for previous cryptococcal fungemia or antigenemia.
The duration of symptoms was shorter in the HIV-infected
patients than in the HIV-uninfected patients (median
duration: 10 days vs. 18 days, p Z 0.048).
In the patients with recorded open pressure during
lumbar puncture, increased pressure (20 cmH2O) wasnfected HIV-uninfected p
37/16 0.125
 7.4 55.3  15.7 <0.001*
(0%) 13/53 (24.5%) 0.015*
(0%) 12/53 (22.6%) 0.028*
(0%) 12/53 (22.6%) 0.028*
(0%) 9/53 (17.0%) 0.100
(0%) 5/53 (9.5%)a 0.316
(0%) 2/53 (3.8%) >0.999
(10.5%)b 6/53 (11.3%)c >0.999
9 (73.7%)d NA NA
(6e140) NA NA
 0.81 NA NA
1.1 4.7  3.4 0.014*
ion.
mia (2/53), rheumatoid arthritis (1/53).
19).
cer (2/53).
, candidiasis (4/19), tuberculosis (3/19), nontuberculosis myco-
Table 2 Presenting clinical symptoms and laboratory data
HIV-infected HIV-uninfected p
Fever, n (%) 7/19 (36.8%) 24/53 (45.3%) 0.524
Headache, n (%) 11/19 (57.9%) 25/53 (47.2%) 0.114
Altered mental status, n (%) 5/19 (26.3%) 25/53 (47.2%) 0.422
Visual symptoms, n (%) 0/19 (0%) 11/53 (20.8%) 0.031*
Auditory symptoms, n (%) 0/19 (0%) 6/53 (11.3%) 0.331
Seizure, n (%) 1/19 (5.3%) 7/53 (13.2%) 0.672
No neurologic symptoms, n (%) 3/19 (15.8%) 0/53 (0%) 0.016*
Symptoms duration, days, median (range)# 10 (0e60) 18 (3e110) 0.048*
Symptoms duration <30 days 13/16 (81.3%) 32/45 (71.7%) 0.428
Open pressure  20 cmH2O, n (%) 9/13 (69.2%) 26/35 (74.3%) 0.728
CSF WBC,/mL median (range)# 2 (0e167) 107 (0e1080) 0.003*
Mononuclear cells predominant, n (%)a 6/7 (85.7%) 31/41 (75.6) >0.999
CSF protein, mg/dL median (range)# 37 (0e173) 106 (1e4500) 0.054
CSF glucose, mg/dL median (range)# 45 (6e65) 35 (1e173) 0.806
CSF culture positive, n (%) 17/19 (89.5%) 32/53 (60.4%) 0.020*
CSF CrAg titer 1:512, n (%) 8/17 (47.1%) 20/47 (42.6%) 0.748
CSF India Ink positive, n (%) 12/18 (66.7%) 28/46 (60.9%) 0.667
Cryptococcemia, n (%) 10/19 (52.6%) 11/53 (20.8%) 0.009*
Serum CrAg titer 1:512, n (%) 8/14 (57.1%) 13/34 (38.2%) 0.230
Other site culture positive, n (%) 1/19 (5.3%)b 4/53 (7.5%)c >0.999
Chest film: mass or nodule lesion, n (%) 8/19 (42.1%) 11/49 (20.8%) 0.105
infiltrates, n (%) 3/19 (15.8%) 12/49 (24.5%) 0.530
Brain image: hydrocephalus, n (%) 4/14 (28.6%) 15/49 (30.6%) 0.553
hypodense lesions, n (%) 5/14 (35.7%) 13/49 (26.5%) 0.986
meningeal enhancement, n (%) 3/14 (21.4%) 4/49 (8.2%) 0.177
CrAg, cryptococcal antigen.
* p < 0.05. #student’s t test.
a Differential counting was only performed as the result of white blood cell count 10/mL.
b Sputum culture.
c Ascites: 1 patient; urine: 3 patients.
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protein levels (pZ 0.054) in the CSF were observed among
the HIV-uninfected patients than in the HIV-infected
patients. No intergroup difference in the proportion of
blood CrAg titers 1:512, CSF CrAg titers 1:512 or positive
CSF staining with India ink was observed between the
groups. More HIV-infected patients, however, yielded
cryptococci in their blood (53% vs. 21%, pZ 0.009) and CSF
(90% vs. 60%, p Z 0.02) than the other group. The most
common presentation on chest films of HIV-infected
patients with CM was mass lesion (42%). In the brain
images, hydrocephalus, hypodense lesions and meningeal
enhancement were commonly reported.
Treatment and outcomes
Excluding the three HIV-uninfected patients who died in the
first 7 days, patients from the two groups who received
each regimen showed no significant differences (Table 3).
The median time to therapy from the time of admission for
HIV-infected and -uninfected patients was 2 days (range:
0e10 days) and 6 days (range: 0e45 days), respectively
(p Z 0.048). Fluconazole was prescribed for consolidation
and maintenance therapy for all patients with complete
induction therapy. For the management of IICP during
admission, six HIV-infected patients (32%) with higher openpressure (mean 36.5  7.6 cmH2O) received temporary
drains, which released pressure by performing frequent and
smaller amounts of CSF drainage several times a day until
the symptoms improved. Other patients (26%) with mild
IICP symptoms received lumbar punctures (2.6  0.9
times). Temporary drains were also inserted in 25% of the
HIV-uninfected patients (mean open pressure: 39.2  17.2
cmH2O) and repeated lumbar punctures (mean 2.8  1.3
times) were administrated in 21% of the patients. For long-
term CSF drainage, permanent shunt devices were inserted
in 26% of the HIV-infected patients and in 19% of the HIV-
uninfected patients. Adjuvant corticosteroid therapy was
prescribed in about one-third of the patients in both
groups.
The mortality rate on day 30 in the HIV-infected patients
was lower than that in the HIV-uninfected patients (0% vs.
18.9%, p Z 0.054), and that on day 90 was significantly
lower than that in the HIV-uninfected group (5.3% vs.
30.8%, p Z 0.029). The Kaplan-Meier survival curves are
shown in Fig. 1 (hazard ratio: 4.45; confidence interval [CI]:
1.04e18.98; p Z 0.038).
One HIV-infected patient and one HIV-uninfected
patient were lost to follow-up (Table 4). Antifungal
therapy was successfully discontinued for at least 1 year in
13 HIV-infected patients (72%) and 27 HIV-uninfected
patients (52%). Three HIV-uninfected patients had
Table 3 Treatment and mortality
HIV-infected HIV-uninfected p
Treatment as antifungal therapy
Amphotericin B alone 10/19 (52.6%) 21/50 (42%) 0.428
Amphotericin B þ flucytosine 1/19 (5.3%) 6/50 (12%) 0.664
Lipid amphotericin B alone 0/19 (0%) 1/50 (2%) >0.999
Lipid amphotericin B þ flucytosine 0/19 (0%) 1/50 (2%) >0.999
Fluconazole alone 7/19 (36.8%) 18/50 (36%) 0.948
Fluconazole þ flucytosine 1/19 (5.3%) 3/50 (6%) >0.999
Treatment for IICP 9/19 (47.4%) 20/53 (37.7%) 0.463
Repeated LP, n (%) 5/19 (26.3%) 11/53 (20.7%) 0.749
Numbers of LP, mean  SD# 2.6  0.9 2.8  1.3 0.835
Temporary drains, n (%) 6/19 (31.6%) 13/53 (24.5%) 0.550
Permanent shunt device, n (%) 5/19 (26.3%) 10/53 (18.9%) 0.521
Adjuvant therapy- corticosteroid 6/19 (31.6%) 17/53 (32.1%) 0.968
Mortality
Day 30 mortality, n (%) 0/19 (0%) 10/53 (18.9%) 0.054
Day 90 mortality, n (%) 1/19 (5.3%) 16/52 (30.8%) 0.029*
CM, cryptococcal meningitis; IICP, increased intracranial pressure; LP, lumbar puncture.
*p < 0.05. #student’s t test.
300 C.-H. Liao et al.improved outcomes. Five HIV-infected patients had unsat-
isfactory outcomes, with:
 two patients relapsing (whose CD4 counts were 150/
mm3 and 105/mm3, respectively, when antifungal
therapy was discontinued after maintenance antifungal
therapy for 320 days and 1302 days, but both died of
CM);
 one death due to CM; and
 two deaths from other causes.
Of the 22 HIV-uninfected patients with unsatisfactory
outcome, 16 died of CM. In patients with satisfactoryFigure 1. Kaplan-Meier survival curve of HIV-infectoutcomes, visual symptoms were only observed in the HIV-
uninfected patients with CM (double vision 3/7; blindness
2/7; blurred vision 2/7). Less than one-third of patients
recovered from CM without any sequela.
On the analysis of the indicators of unsatisfactory
outcomes (Table 5), we found that an initial CD4 count
20/mm3 was a significant indicator of unsatisfactory
outcomes in the HIV-infected patients (odds ratio [OR]:
18.0; 95% CI: 1.19-271.46; p Z 0.037). On the other hand,
corticosteroid use, advanced liver cirrhosis, altered mental
status, cryptococcemia, CSF CrAg  1:512 and hydroceph-
alus, however, were significant indicators of unsatisfactory
outcomes in HIV-uninfected group among univariateed patients and HIV-uninfected patients with CM.
Table 4 Treatment outcomes and sequelae
HIV-infected HIV-uninfected p
Lost to follow-up, n (%) 1/19 (5.3%) 1/53 (1.9%) 0.461
Satisfactory outcomes, n (%) 13/18 (72.2%) 30/52 (57.7%) 0.275
Cure/success, n (%) 13/18 (72.2%) 27/52 (51.9%) 0.134
Improved, n (%) 0/18 (0.0%) 3/52 (5.8%) 0.564
Unsatisfactory outcomes, n (%) 5/18 (27.8%) 22/52 (42.3%) 0.275
Fail, n (%) 1/18 (5.6%) 16/52 (30.8%) 0.052
Relapse, n (%) 2/18 (11.1%) 0/52 (0.0%) 0.063
Indeterminate, n (%) 2/18 (11.1%) 6/52 (11.5%) >0.999
Sequelae, n (%) 9/13 (69.2%) 22/30 (73.3%) >0.999
Headache, n (%) 5/13 (38.5%) 3/30 (10%) 0.042*
Dizziness/vertigo, n (%) 2/13 (15.4%) 4/30 (13.3%) >0.999
Hemiparesis, n (%) 2/13 (15.4%) 5/30 (16.7%) >0.999
Visual, n (%) 0/13 (0.0%) 7/30 (23.3%) 0.082
Auditory, n (%) 1/13 (7.7%) 5/30 (16.7%) 0.649
Seizure, n (%) 1/13 (7.7%) 3/30 (10%) >0.999
CM, cryptococcal meningitis.
*p < 0.05.
Cryptococcal meningitis in adult 301analysis. Hydrocephalus (OR: 8.7; 95% CI: 2.23e28.98;
p Z 0.003) and CSF CrAg 1:512 (OR: 16.2; 95% CI:
1.36e192.02; p Z 0.027) were significant indicators in the
multivariate analysis.Discussion
Our results demonstrated some differences between HIV-
infected and HIV-uninfected patients with CM. HIV-infected
patients were significantly younger and easily yielded
cryptococci in the blood and CSF. More HIV-uninfected
patients presented with visual symptoms, a higher degree
of pleocytosis and higher protein levels in the CSF. In
addition to receiving repeated lumbar punctures, tempo-
rary drains and permanent shunts were frequentlyTable 5 Indicators of unsatisfactory outcomes after treatment o
meningitis
Factors Univar
OR (95%CI)
HIV-infected with CM
CD4  20/mm3 at CM presentation 18.0 (1.19e271.46
Altered mental status 8.25 (0.79e85.56)
CSF CrAg 1:512 9.0 (0.75e108.31)
HIV-uninfected with CM
Age 60 2.4 (0.78e7.44)
Corticosteroid use 4.5 (1.16e17.41)
Advanced liver cirrhosis 10.86 (1.20e98.47
Altered mental status 4.29 (1.32e13.88)
CSF CrAg 1:512 5.31 (1.51e18.69)
Cryptococcemia 9.69 (1.83e51.35)
Hydrocephalus 13.00 (2.92e57.85
CM, cryptococcal meningitis; CSF, cerebrospinal fluid; CrAg, cryptoco
*p < 0.05.administrated in both groups for CSF drainage. HIV-infected
patients had significantly lower mortality rate. Finally,
different groups showed different indicators of unsatisfac-
tory outcomes.
In contrast to earlier reports,12,17,18 we found that old
age and a high proportion of predisposing factors were
common to our HIV-uninfected patients with CM. These
findings were also reported by Lee et al from Taiwan.11 Like
others,3,6,8e11 we found that HIV-infected patients with CM
were mostly young males with AIDS status, consistent with
the age distribution of HIV-infected patients in Taiwan.
Similar to the findings in prior reports,4,7,11,12 fever and
headache were the most common initial symptoms in both
groups, but a trend towards more altered mental status was
observed in the HIV-uninfected group. Although more HIV-
infected patients presented with subtle neurologicalf HIV-infected and HIV-uninfected patients with cryptococcal
iate Multivariate
p OR (95%CI) p
) 0.037* 18.0 (1.19e271.46) 0.037*
0.077
0.118
0.129
0.031*
) 0.034*
0.015*
0.009* 16.2 (1.37e192.02) 0.027*
0.008*
) 0.001* 8.7 (2.23e28.98) 0.003*
ccal antigen.
302 C.-H. Liao et al.symptoms, the symptom duration in these patients was
shorter than that in the HIV-uninfected patients. This may
result from clinicians’ higher degree of suspicion on
opportunistic infection in HIV-confirmed patients.
In agreement with the literatures,8,11,19 HIV-uninfected
patients had a higher degree of pleocytosis and higher
protein levels in the CSF, but fewer patients yielded cryp-
tococci in CSF and blood, which might be explained by the
higher severity of inflammation and lower fungal burdens in
the HIV-uninfected patients.2,8 Pulmonary cryptococcosis
with CNS involvement was identified in more immune-
compromised patients20,21 and concurrent pulmonary
infections might be an alternative suspicion in these indi-
viduals. Hydrocephalus, hypodense lesions and meningeal
enhancement were common presentations in brain images,
with varying proportions in the literature 11,18,22 and in our
study.
For treatment of CM, amphotericin-B-based therapy is
the first choice, as recommended in the guideline,14,15 but
this drug was not used exclusively in our study or
others.8,9,11,17 A higher proportion of predisposing factors
and intolerable side-effects may influence clinicians to
choose or change a regimen.
For managing IICP, repeated lumbar punctures or surgical
drains are suggested as a therapeutic option by the guide-
lines15 and literature.8,11,23,24 In many studies, patients
received lumbar punctures rather than drains,8,11,19,25 as
surgeons might be less disposed to perform surgical inter-
ventions in HIV-infected patients.8 In our study, a high
proportion of drains or shunts were inserted in both groups,
and this may be attributed to the adequate support of
neurosurgeons.
A lower mortality rate was observed in HIV-infected
patients. Similar results were also noted in a prospective
multicenter study, which summarized that a more intact
immune response may contribute to increased CNS-related
morbidity and overall mortality,8 but this was not compat-
ible with the findings of other retrospective studies.11,12
Earlier diagnosis and intensive treatment of IICP in our
HIV-infected patients might be the reason for the reduced
mortality in our group. High intracranial pressure was an
important factor associated with early mortality in HIV-
infected patients.26 In a histopathological study of HIV-
infected patients with high open pressure, larger amounts
of cryptococci and greater inflammation response were
observed over arachnoid granulations, which might impair
CSF reabsorption.27 A prominent immune response in the
CNS might contribute to more severe obstruction of CSF
outflow and higher mortality, but AIDS patients with CM
would have little inflammatory response in the CSF.8,28
Their IICP is associated with a higher fungal load, and
mechanical drainage of CSF may be helpful to decompress
the obstruction and remove fungal polysaccharides.24 In
some situations, however, brain herniation might be
a concern when a large volume of CSF has been drained
through lumbar punctures for extremely high pressure.29
Frequent lumbar punctures for CSF drainage may increase
the suffering of patients and reduce the likelihood of
procedure performance by clinicians. In our study, tempo-
rary drains and permanent shunts were often used in
patients with higher intercranial pressure. None of the HIV-
infected patients with IICP died within 10 weeks. Highmortality rates were, however, observed at 2 weeks (2/13,
15%) and 10 weeks (7/13, 58%) among the HIV-uninfected
patients who had received temporary drains. Although
aggressive decompression was performed for these
patients, prominent inflammation may have been ongoing,
thereby leading to more complications, irreversible brain
damage and higher mortality.8,28 This inference needs to be
confirmed by larger multicenter randomized studies.
Prolonged antifungal therapy until immune restoration
with ART to reduce relapse was recommended in patients
with HIV.15,21,30 In two patients, however, relapses occurred
after antifungal therapywas discontinued although their CD4
counts were >100/mm3 after ART, and this has been previ-
ously reported.31
Twenty-two HIV-uninfected patients had unsatisfactory
outcomes, but without relapse. A combination of brain
lesions and inflammation may contribute to most sequelae.
Uncontrolled IICP was also mentioned and may be associ-
ated with visual or auditory impairment32,33 but these
sequelae were still observed, even after intensive treat-
ment for IICP, and may be attributed to delayed interven-
tion and irreversible damage.
Indicators of unsatisfactory outcomes in HIV-uninfected
patients with CM are well described and include cortico-
steroid use, fungemia, semicoma and initial CSF CrAg
1:512.4,16 Liver cirrhosis and advanced age are also asso-
ciated with poor prognoses for patients with cryptococce-
mia.9 In addition, hydrocephalus may be attributed to CSF
malabsorption and had poor outcome in patients.18 We
obtained similar results in our multivariate analysis, and
these results suggest that this condition may result from
prolonged inflammation in the CNS and delayed diagnosis.
In HIV-infected patients, a CD4 count 20/mm3 at CM
presentation was associated with death or relapse in
multivariate analysis. The mean CD4 counts were also
significantly different (satisfactory outcomes vs. unsatis-
factory outcomes: 16.6  10.1 vs. 65.7  44.7, pZ 0.031).
An initial low CD4 count was an important poor prognostic
factor for all AIDS patients, regardless of whether in the
pre-ART or post-ART era.34e36 Patients with extremely low
CD4 counts may have a higher risk of early death because of
concurrent complicated problems, and they may show
a higher probability of contracting new infections during
a longer immune restoration period.36
There are some limitations in our study. First, the low
use of lipid amphotericin B and flucytosine in our patients
made it difficult to investigate their influences on
outcomes. Second, the variant presentations and prognoses
of different serotypes of Cryptococcus were documented,37
but further identification was not pursued in our study.
Third, the small sample size in our study may have led to
the under-estimation of some of the significant factors.
There are differences in the clinical presentations and
mortality rates of CM between patients with and patients
without HIV infection. Extremely low CD4 cell counts (20/
mm3) in HIV-infected patients and marked hydrocephalus in
HIV-uninfected patients was associated with unsatisfactory
outcomes. In addition to these, both cryptococci and
intensity of inflammation in the CNS may also play impor-
tant roles in the pathogenesis of CM. Early diagnosis to
prevent the formation of marked hydrocephalus and
surgical intervention to drain the cryptococci and release
Cryptococcal meningitis in adult 303IICP may improve the outcome of patients with CM, espe-
cially those with HIV infection.Acknowledgments
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